Icahn goes in for the kill at Amylin

Carl Icahn has found a new opening to push Amylin's board to sell the company. In an open letter, the feared raider lambasted the company ($AMLN) for handing out stock options at $16 a share when it was keeping quiet about Bristol-Myers Squibb's ($BMY) $22 a share bid. And he described the board as "dysfunctional." Icahn, of course, has specialized in buying into biotechs like Biogen Idec ($BIIB) and Genzyme at a time of weakness and then kicking down the doors in pursuit of a sale at a significant premium over what he paid for shares. He's also had a remarkable success rate. Amylin now gets to enjoy the full Icahn treatment, and all that that entails. Report

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.